(Q35683565)

9 August 2017

1 reference

title

1. Peroxisome proliferator-activated receptor gamma (PPARgamma) ligands and their therapeutic utility (English)

1 reference

9 August 2017

Brad R Henke

1

1 reference

9 August 2017

publication date

1 January 2004

1 reference

Progress in medicinal chemistry

9 August 2017

published in

1 reference

9 August 2017

volume

42

1 reference

9 August 2017

page(s)

1-53

1 reference

The RXR heterodimers and orphan receptors

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

A unified nomenclature system for the nuclear receptor superfamily

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARalpha

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Structure of the PPARalpha and -gamma ligand binding domain in complex with AZ 242; ligand selectivity and agonist activation in the PPAR family

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Molecular recognition of fatty acids by peroxisome proliferator-activated receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Differential expression and activation of a family of murine peroxisome proliferator-activated receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Peroxisome proliferator activated receptors: transcriptional regulators of adipogenesis, lipid metabolism and more....

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

PPAR gamma 2 regulates adipose expression of the phosphoenolpyruvate carboxykinase gene

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Induction of the acyl-coenzyme A synthetase gene by fibrates and fatty acids is mediated by a peroxisome proliferator response element in the C promoter

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Nuclear hormone receptors and cholesterol trafficking: the orphans find a new home

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

PPARs: transcription factors controlling lipid and lipoprotein metabolism.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Peroxisome proliferator activated receptors and obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

The mechanisms of action of PPARs

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Do peroxisome proliferating compounds pose a hepatocarcinogenic hazard to humans?

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

The organization, promoter analysis, and expression of the human PPARgamma gene

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

PPARgamma3 mRNA: a distinct PPARgamma mRNA subtype transcribed from an independent promoter

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

PPARgamma knockdown by engineered transcription factors: exogenous PPARgamma2 but not PPARgamma1 reactivates adipogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Genetic analysis of adipogenesis through peroxisome proliferator-activated receptor gamma isoforms

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Ligand-independent activation domain in the N terminus of peroxisome proliferator-activated receptor gamma (PPARgamma). Differential activity of PPARgamma1 and -2 isoforms and influence of insulin

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

PPARgamma: an essential regulator of adipogenesis and modulator of fat cell function

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Regulation of adipogenesis and energy balance by PPARgamma and PGC-1

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

PPAR-gamma: adipogenic regulator and thiazolidinedione receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARalpha and PPARgamma activators

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Altered gene expression for tumor necrosis factor-alpha and its receptors during drug and dietary modulation of insulin resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Sulfated glycans stimulate endocytosis of the cellular isoform of the prion protein, PrPC, in cultured cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Development of a scintillation proximity assay for peroxisome proliferator-activated receptor gamma ligand binding domain

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Fatty acids activate a chimera of the clofibric acid-activated receptor and the glucocorticoid receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

The TRAP220 component of a thyroid hormone receptor- associated protein (TRAP) coactivator complex interacts directly with nuclear receptors in a ligand-dependent fashion

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Activation of PPARgamma coactivator-1 through transcription factor docking

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Peroxisome proliferator-activated receptors and retinoic acid receptors differentially control the interactions of retinoid X receptor heterodimers with ligands, coactivators, and corepressors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

p300 functions as a coactivator for the peroxisome proliferator-activated receptor alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Nuclear receptors have distinct affinities for coactivators: characterization by fluorescence resonance energy transfer.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Multiplexed molecular interactions of nuclear receptors using fluorescent microspheres

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Prostaglandin J2 and its metabolites promote neurite outgrowth induced by nerve growth factor in PC12 cells

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Biological actions of delta 12-prostaglandin J2.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARgamma agonist

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Direct thiazolidinedione action on isolated rat skeletal muscle fuel handling is independent of peroxisome proliferator-activated receptor-gamma-mediated changes in gene expression

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-alpha (PPAR-alpha) and PPAR-gamma: effect of PPAR-alpha activation on abnormal lipid metabolism in liver of Zucker fatty rats

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Studies on antidiabetic agents. II. Synthesis of 5-[4-(1-methylcyclohexylmethoxy)-benzyl]thiazolidine-2,4-dione (ADD-3878) and its derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Studies on antidiabetic agents. I. Synthesis of 5-[4-(2-methyl-2-phenylpropoxy)-benzyl]thiazolidine-2,4-dione (AL-321) and related compounds

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Studies on antidiabetic agents. 11. Novel thiazolidinedione derivatives as potent hypoglycemic and hypolipidemic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Studies on hindered phenols and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

[[omega-(Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Molecular design, synthesis, and hypoglycemic activity of a series of thiazolidine-2,4-diones

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Novel thiazolidine-2,4-diones as potent euglycemic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Novel antidiabetic and hypolipidemic agents. 5. Hydroxyl versus benzyloxy containing chroman derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Substituted dihydrobenzopyran and dihydrobenzofuran thiazolidine-2,4-diones as hypoglycemic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Hypoglycemic activity of a series of alpha-alkylthio and alpha-alkoxy carboxylic acids related to ciglitazone

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Novel benzoxazole 2,4-thiazolidinediones as potent hypoglycemic agents. Synthesis and structure-activity relationships

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Synthesis and antihyperglycemic activity of novel 5-(naphthalenylsulfonyl)-2,4-thiazolidinediones

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

A new thiazolidinedione, NC-2100, which is a weak PPAR-gamma activator, exhibits potent antidiabetic effects and induces uncoupling protein 1 in white adipose tissue of KKAy obese mice

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Chronic and acute effects of thiazolidinediones BM13.1258 and BM15.2054 on rat skeletal muscle glucose metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Studies on antidiabetic agents. VI. Asymmetric transformation of (+/-)-5-[4-(1-methylcyclohexylmethoxy)benzyl]-2,4- thiazolidinedione(ciglitazone) with optically active 1-phenylethylamines

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Differential activity of rosiglitazone enantiomers at PPAR gamma

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Benzyloxazolidine-2,4-diones as potent hypoglycemic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Hydroxyurea derivatives as hypoglycemic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Antihyperglycemic activity of novel substituted 3H-1,2,3,5-oxathiadiazole 2-oxides

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Antihyperglycemic activity of novel naphthalenyl 3H-1,2,3,5-oxathiadiazole 2-oxides

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

New potent antihyperglycemic agents in db/db mice: synthesis and structure-activity relationship studies of (4-substituted benzyl) (trifluoromethyl)pyrazoles and -pyrazolones

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Studies on new acidic azoles as glucose-lowering agents in obese, diabetic db/db mice

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Novel 5-substituted-1H-tetrazole derivatives as potent glucose and lipid lowering agents

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Isoxazolidine-3,5-dione and noncyclic 1,3-dicarbonyl compounds as hypoglycemic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Novel 5-substituted 2,4-thiazolidinedione and 2,4-oxazolidinedione derivatives as insulin sensitizers with antidiabetic activities

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Studies on non-thiazolidinedione antidiabetic agents. 1. Discovery of novel oxyiminoacetic acid derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Non-thiazolidinedione antihyperglycaemic agents. Part 3: The effects of stereochemistry on the potency of alpha-methoxy-beta-phenylpropanoic acids

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 2. Structure-activity relationship and optimization of the phenyl alkyl ether moiety

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 3. Structure-activity relationship and optimization of the N-aryl substituent

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Synthesis and biological activity of L-tyrosine-based PPARgamma agonists with reduced molecular weight

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Peroxisome proliferator-activated receptor (PPAR) modulators: diabetes and beyond

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Synthesis and biological activity of a novel series of indole-derived PPARgamma agonists

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

The PPARs: from orphan receptors to drug discovery

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Lipid metabolism: peroxisome proliferator-activated receptor-alpha and atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

PPARS, metabolic disease and atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

(3-substituted benzyl)thiazolidine-2,4-diones as structurally new antihyperglycemic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Tissue-specific actions of antidiabetic thiazolidinediones on the reduced fatty acid oxidation in skeletal muscle and liver of Zucker diabetic fatty rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Amelioration by KRP-297, a new thiazolidinedione, of impaired glucose uptake in skeletal muscle from obese insulin-resistant animals

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

(-)3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid [(-)DRF 2725]: a dual PPAR agonist with potent antihyperglycemic and lipid modulating activity

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

AZ 242, a novel PPARalpha/gamma agonist with beneficial effects on insulin resistance and carbohydrate and lipid metabolism in ob/ob mice and obese Zucker rats

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Identification of a series of oxadiazole-substituted alpha-isopropoxy phenylpropanoic acids with activity on PPARalpha, PPARgamma, and PPARdelta

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Design and synthesis of 2-methyl-2-[4-(2-[5-methyl-2-aryloxazol-4-yl]ethoxy)phenoxy]propionic acids: a new class of dual PPARalpha/gamma agonists

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Identification of a series of PPAR gamma/delta dual agonists via solid-phase parallel synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Design and synthesis of novel PPARalpha/gamma/delta triple activators using a known PPARalpha/gamma dual activator as structural template

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

L-764406 is a partial agonist of human peroxisome proliferator-activated receptor gamma. The role of Cys313 in ligand binding

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Synthesis and pharmacological evaluation of a new class of peroxisome proliferator-activated receptor modulators

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

T0070907, a selective ligand for peroxisome proliferator-activated receptor gamma, functions as an antagonist of biochemical and cellular activities

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

A new selective peroxisome proliferator-activated receptor gamma antagonist with antiobesity and antidiabetic activity

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor gamma-activating properties

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

The development of overt diabetes in young Zucker Diabetic Fatty (ZDF) rats and the effects of chronic MCC-555 treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Novel euglycemic and hypolipidemic agents. 4. Pyridyl- and quinolinyl-containing thiazolidinediones

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

A synthetic antagonist for the peroxisome proliferator-activated receptor gamma inhibits adipocyte differentiation

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Bisphenol a diglycidyl ether (BADGE) suppresses tumor necrosis factor-alpha production as a PPARgamma agonist in the murine macrophage-like cell line, RAW 264.7.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Bisphenol A diglycidyl ether (BADGE) is a PPARgamma agonist in an ECV304 cell line

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Crystal structure of the ligand binding domain of the human nuclear receptor PPARgamma

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Asymmetry in the PPARgamma/RXRalpha crystal structure reveals the molecular basis of heterodimerization among nuclear receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Coactivator and corepressor complexes in nuclear receptor function

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Ligand-induced stabilization of PPARgamma monitored by NMR spectroscopy: implications for nuclear receptor activation

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Rationale for and role of thiazolidinediones in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Insulin resistance and its treatment by thiazolidinediones

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

New perspectives into the molecular pathogenesis and treatment of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Pioglitazone enhances splanchnic glucose uptake as well as peripheral glucose uptake in non-insulin-dependent diabetes mellitus. AD-4833 Clamp-OGL Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Effect of Troglitazone on B Cell Function, Insulin Sensitivity, and Glycemic Control in Subjects with Type 2 Diabetes Mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study. The Troglitazone Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

1 reference

7 January 2021

Glitazones: clinical effects and molecular mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Differentiating members of the thiazolidinedione class: a focus on safety

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Regulation of PPAR gamma gene expression by nutrition and obesity in rodents.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Troglitazone action is independent of adipose tissue

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Adipogenesis and obesity: rounding out the big picture

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Altered tumor necrosis factor-alpha (TNF-alpha) processing in adipocytes and increased expression of transmembrane TNF-alpha in obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Modulation of insulin activities by leptin

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor gamma

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

The role of long-chain fatty acyl-CoA esters in beta-cell signal transduction

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

The mode of action of thiazolidinediones

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Pharmacogenetic evidence that cd36 is a key determinant of the metabolic effects of pioglitazone

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Regulatory interactions between lipids and carbohydrates: the glucose fatty acid cycle after 35 years.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor gamma activation has coordinate effects on gene expression in multiple insulin-sensitive tissues

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Intramyocellular lipid and insulin resistance: a longitudinal in vivo 1H-spectroscopic study in Zucker diabetic fatty rats

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Pioglitazone-induced increase of insulin sensitivity in the muscles of the obese Zucker fa/fa rat cannot be explained by local adipocyte differentiation

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Obesity associated with a mutation in a genetic regulator of adipocyte differentiation

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Two Polymorphisms in the Peroxisome Proliferator-Activated Receptor- Gene Are Associated with Severe Overweight among Obese Women

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

A genetic polymorphism of the peroxisome proliferator-activated receptor gamma gene influences plasma leptin levels in obese humans

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic Caucasians: identification of a Pro12Ala PPAR gamma 2 missense mutation

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

The peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

PPAR gamma is required for placental, cardiac, and adipose tissue development

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

PPARgamma, the ultimate thrifty gene

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Insulin resistance and cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Insulin resistance implications for type II diabetes mellitus and coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Lipid response to pioglitazone in diabetic patients: clinical observations from a retrospective chart review

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Improved glycemic control and lipid profile in a randomized study of pioglitazone compared with acarbose in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Differences in lipid profiles of patients given rosiglitazone followed by pioglitazone

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-alpha/gamma agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical mode

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Fenofibrate prevents and reduces body weight gain and adiposity in diet-induced obese rats

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Peroxisome proliferators: mechanisms of adverse effects in rodents and molecular basis for species differences

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Control mechanisms of the oscillations of insulin secretion in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Emerging roles of PPARs in inflammation and immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Peroxisome proliferator-activated receptor gamma agonists: potential use for treating chronic inflammatory diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Regulation of the Hedgehog and Wingless signalling pathways by the F-box/WD40-repeat protein Slimb

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Rosiglitazone (PPARgamma-agonist) attenuates atherogenesis with no effect on hyperglycaemia in a combined diabetes-atherosclerosis mouse model

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: a serial intravascular ultrasound study

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Troglitazone improves psoriasis and normalizes models of proliferative skin disease: ligands for peroxisome proliferator-activated receptor-gamma inhibit keratinocyte proliferation

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

15-deoxy-delta(12,14)-PGJ(2) induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Transcription-modulating drugs: a new frontier in the treatment of essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Effects of the thiazolidinediones on cardiovascular risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Antihypertensive effect of pioglitazone is not invariably associated with increased insulin sensitivity.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Attenuation of hypertension by insulin-sensitizing agents

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Effects of pioglitazone in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Does insulin dysfunction play a role in Alzheimer's disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Inflammation and Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

PPARgamma induces cell cycle withdrawal: inhibition of E2F/DP DNA-binding activity via down-regulation of PP2A.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Terminal differentiation of human breast cancer through PPAR gamma

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-gamma agonists through induction of apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Expression of peroxisome proliferator-activated receptor gamma in renal cell carcinoma and growth inhibition by its agonists

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Activation of PPARgamma inhibits cell growth and induces apoptosis in human gastric cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

APC-dependent suppression of colon carcinogenesis by PPARgamma

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Activators of the nuclear receptor PPARgamma enhance colon polyp formation

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

The nuclear eicosanoid receptor, PPARgamma, is aberrantly expressed in colonic cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Expression of the peroxisome proliferator-activated receptor (PPAR) in the mouse colonic mucosa

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Loss-of-Function Mutations in PPARγ Associated with Human Colon Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Activation of PPARgamma leads to inhibition of anchorage-independent growth of human colorectal cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Activation of the peroxisome proliferator-activated receptor γ promotes the development of colon tumors in C57BL/6J-APCMin/+ mice

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

The peroxisome proliferator-activated receptor delta, an integrator of transcriptional repression and nuclear receptor signaling

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

n-6 and n-3 essential fatty acids in rheumatoid arthritis and other rheumatic conditions.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Essential fatty acids and polyunsaturated fatty acids: significance in cutaneous biology

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Dietary fats and cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Dietary fat and breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Diet and breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Exploring the metabolic and genetic control of gene expression on a genomic scale

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Pharmacological profiles of a novel oral antidiabetic agent, JTT-501, an isoxazolidinedione derivative

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

Muscle long-chain acyl CoA esters and insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2804%2942001-3

7 January 2021

10.1016/S0079-6468(04)42001-3

Identifiers

DOI

0 references

Fatcat ID

release_ftpq6p45jnbktnz32bgiix3ska

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ftpq6p45jnbktnz32bgiix3ska

24 November 2022

mapped directly with Wikidata item

1 reference